Logo image of GSD.CA

DEVONIAN HEALTH GROUP INC (GSD.CA) Stock Price, Forecast & Analysis

Canada - TSX-V:GSD - CA2518348008 - Common Stock

0.2 CAD
+0.01 (+2.56%)
Last: 11/13/2025, 7:00:00 PM

GSD.CA Key Statistics, Chart & Performance

Key Statistics
Market Cap32.80M
Revenue(TTM)32.94M
Net Income(TTM)-5.16M
Shares163.98M
Float143.23M
52 Week High0.35
52 Week Low0.08
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.03
PEN/A
Fwd PEN/A
Earnings (Next)11-27 2025-11-27
IPO2014-09-09
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


GSD.CA short term performance overview.The bars show the price performance of GSD.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40

GSD.CA long term performance overview.The bars show the price performance of GSD.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 -40

The current stock price of GSD.CA is 0.2 CAD. In the past month the price increased by 53.85%. In the past year, price decreased by -9.09%.

DEVONIAN HEALTH GROUP INC / GSD Daily stock chart

GSD.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
BHC.CA BAUSCH HEALTH COS INC 1.65 3.26B
TLRY.CA TILRAY BRANDS INC N/A 1.71B
CRON.CA CRONOS GROUP INC 24.64 1.32B
DHT-UN.CA DRI HEALTHCARE TRUST 7.39 885.25M
DHT-U.CA DRI HEALTHCARE TRUST 5.26 623.65M
GUD.CA KNIGHT THERAPEUTICS INC 122.8 612.04M
WEED.CA CANOPY GROWTH CORP N/A 510.76M
ACB.CA AURORA CANNABIS INC N/A 339.75M
CPH.CA CIPHER PHARMACEUTICALS INC 20.55 332.96M
HITI.CA HIGH TIDE INC N/A 331.47M
OGI.CA ORGANIGRAM GLOBAL INC N/A 283.44M
NGEN.CA NERVGEN PHARMA CORP N/A 244.46M

About GSD.CA

Company Profile

GSD logo image Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Montmagny, Quebec and currently employs 6 full-time employees. The company went IPO on 2014-09-09. The company specializes in the development of drugs for various autoimmune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. The company is developing prescription drugs for the treatment of inflammatory autoimmune diseases, including but not limited to, ulcerative colitis and atopic dermatitis. The company is also involved in the development of cosmeceutical products, leveraging the same proprietary approach employed with their pharmaceutical offerings. Its flagship product, Thykamine, is a pharmaceutical product issued from its SUPREX platform, for the prevention and treatment of health problems related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune diseases. Its cosmeceutical products include R-Spinasome and Purgenesis. Its subsidiary, Altius Healthcare Inc., sells prescription pharmaceutical products.

Company Info

DEVONIAN HEALTH GROUP INC

360 rue des Entrepreneurs

Montmagny QUEBEC G5V 4T1 CA

CEO: Andre P. Boulet

Employees: 7

GSD Company Website

GSD Investor Relations

Phone: 15142487509

DEVONIAN HEALTH GROUP INC / GSD.CA FAQ

What does GSD do?

Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Montmagny, Quebec and currently employs 6 full-time employees. The company went IPO on 2014-09-09. The company specializes in the development of drugs for various autoimmune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. The company is developing prescription drugs for the treatment of inflammatory autoimmune diseases, including but not limited to, ulcerative colitis and atopic dermatitis. The company is also involved in the development of cosmeceutical products, leveraging the same proprietary approach employed with their pharmaceutical offerings. Its flagship product, Thykamine, is a pharmaceutical product issued from its SUPREX platform, for the prevention and treatment of health problems related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune diseases. Its cosmeceutical products include R-Spinasome and Purgenesis. Its subsidiary, Altius Healthcare Inc., sells prescription pharmaceutical products.


What is the current price of GSD stock?

The current stock price of GSD.CA is 0.2 CAD. The price increased by 2.56% in the last trading session.


What is the dividend status of DEVONIAN HEALTH GROUP INC?

GSD.CA does not pay a dividend.


How is the ChartMill rating for DEVONIAN HEALTH GROUP INC?

GSD.CA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the sector and industry classification for DEVONIAN HEALTH GROUP INC?

DEVONIAN HEALTH GROUP INC (GSD.CA) operates in the Health Care sector and the Pharmaceuticals industry.


Can you provide the market cap for DEVONIAN HEALTH GROUP INC?

DEVONIAN HEALTH GROUP INC (GSD.CA) has a market capitalization of 32.80M CAD. This makes GSD.CA a Nano Cap stock.


GSD.CA Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to GSD.CA. When comparing the yearly performance of all stocks, GSD.CA is one of the better performing stocks in the market, outperforming 72.22% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

GSD.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to GSD.CA. While GSD.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GSD.CA Financial Highlights

Over the last trailing twelve months GSD.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by -60.37% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -22.47%
ROE -58.41%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%-1146.15%
Sales Q2Q%43.66%
EPS 1Y (TTM)-60.37%
Revenue 1Y (TTM)237.82%

GSD.CA Forecast & Estimates


Analysts
Analysts0
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

GSD.CA Ownership

Ownership
Inst OwnersN/A
Ins Owners12.65%
Short Float %N/A
Short RatioN/A